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Rationale: Optimal pre-hospital delivery pathways for acute stroke patients suspected to 
harbor a large vessel occlusion (LVO) have not been assessed in randomized trials. 
Aim: To establish whether stroke subjects with RACE scale based suspicion of LVO 
evaluated by Emergency Medical Services in the field, have higher rates of favorable 
outcome when transferred directly to an Endovascular Center (EVT-SC), as compared 
to the standard transfer to the closest Local Stroke Center (Local-SC).
Design: Multicenter, superiority, cluster randomized within a cohort trial with blinded 
endpoint assessment. 
Procedure: Eligible patients must be 18 or older, have acute stroke symptoms and not 
have an immediate life threatening condition requiring emergent medical intervention. 
They must be suspected to have intracranial LVO based on a pre-hospital RACE scale 
of ≥5, be located in geographical areas where the default health authority assigned 
referral stroke center is a non-thrombectomy capable hospital, and estimated arrival at a 
thrombectomy capable stroke hospital in less than 7 hours from time last seen well. 
Cluster randomization is performed according to a pre-established temporal sequence 
(temporal cluster design) with 3 strata: day/night, distance to the EVT-SC and 
week/week-end day. 
Study outcome: The primary endpoint is the modified Rankin Scale (mRS) score at 90 
days. The primary safety outcome is mortality at 90 days. 
Analysis: The primary endpoint based on the modified intention-to-treat population is 
the distribution of modified Rankin Scale scores (mRS) at 90 days analyzed under a 
sequential triangular design. The maximum sample size is 1754 patients, with two 
planned interim analyses when 701 (40%) and 1227 patients have completed follow-up.  
Hypothesized common odds ratio is 1.35.




Despite the proven efficacy of intravenous (iv) thrombolysis in acute stroke patients, 
outcomes remain poor in those patients with occlusion of proximal large intracranial 
arteries1. The efficacy of iv thrombolysis in terms of arterial recanalization in the first 
hours progressively drops as the burden of the occlusive clot increases.2 While the 
recanalization rate of an M2 occlusion is around 70%, the recanalization rates of M1 or 
terminal ICA occlusions drop to 30% and 10% respectively3. In patients with proximal 
LVO, the main advantage of iv thrombolysis treatment is that the treatment is readily 
available and can be promptly instituted even at centers lacking a sophisticated 
infrastructure. 
On the other hand, endovascular treatment (EVT) has been shown to be a powerful 
treatment in patients with LVO stroke whether or not pre-treated wih iv t-PA, largely 
because effective reperfusion rates observed with this procedure are in the 80% range.4 
The counterpart is that, due to the nature of this treatment, a high level of technological 
resources and specialized physicians are needed, limiting the availability of this 
treatment to comprehensive stroke centers. This fact challenges the geographic equity in 
the access to EVT.
It seems clear that in the following years the number of trained interventionalists will 
grow and new EVT capable centers will appear. Still the presence of EVT capable 
centers in remote areas with low population density will not be justified.
At present we have 2 different strategies to manage stroke patients suspected to harbor a 
large vessel occlusion located in geographical areas not primarily covered by a EVT-
SC. Transfer to the nearest primary stroke center where iv t-PA is administered with 
subsequent transfer to an endovascular center in case of LVO vs primary stroke center 
bypass and direct transfer to an endovascular center where both iv t-PA (if eligible) and 
endovascular treatment can be administered.  While time to treatment initiation is of 
critical importance, in the first case iv t-PA is presumed to be administered faster but 
may not be effective in a large proportion of patients with proximal LVO, and a 
secondary transfer to an endovascular center implies a delay of time from onset to 
recanalization.5 Conversely, adirect transfer to an endovascular center would result in 
faster initiation of thrombectomy at the presumed expense of delayed or even denied 
administration of iv t-PA. It is worth highlighting that only about 25-30% of patients 
selected with a RACE>4 are candidate to iv-tPA.6 In both scenarios, time to treatment 
initiation is critical and the sooner the treatment is started, the higher are the chances of 
clinical recovery.7 Currently, no randomized data are available to support the benefit of 
one approach versus the other.
In addition, several other issues should be considered. How safe is it to transfer these 
patients to more distant hospitals? Is there a distance beyond which there is no or very 
limited benefit from a direct transfer to an EVT-SC? 
Theoretically the benefits of a primary transfer to an EVT-SC would only apply to 
patients with LVO and may unnecessarily delay treatment in all others. Therefore, the 
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predictive power of initial screening tools to identify patients with suspected LVO 
becomes of paramount importance. In our region we have developed the RACE scale 
which has been validated as a reliable tool for predicting the presence of LVO with 
approximately 50% predictive power including when used by paramedics region-wide.8
The overall goal of the RACECAT trial is to establish whether subjects with clinically 
suspected LVO at the pre-hospital level (established by a RACE scale score >4) and 
transferred directly to an EVT-SC, thus bypassing the local-SC, have a more favorable 
clinical outcome as compared with subjects transferred to the closest local stroke center. 
The RACECAT trial aims to provide answers to important logistic questions to 
streamline acute stroke systems of care and access to specific reperfusion treatments. 
METHODS
Study design
RACECAT is a cluster randomized, mirroring real world care trial, with blinded-end-
point assessment, that is embedded within a region-wide registry of acute stroke patients 
(CICAT) and focuses on patients with suspected acute large vessel occlusion (LVO) 
identified by Emergency Medical Services (EMS) at first assistance in the field. Two 
EMS routing strategies are compared: transfer to the closest local stroke center (Local-
SC) vs. transfer to an endovascular stroke center (EVT-SC), according to a pre-
established temporal sequence that remains concealed to the EMS technicians before the 
first patient within the cluster is transferred.
Option 1: Transfer to the nearest local-SC offers immediate care including rapid access 
to iv-thrombolysis. For LVO patients, subsequent transfer to an EVT-SC is organized, 
where the patient can arrive: recanalized (no further specific treatment needed), with a 
large infarct and no mismatch (no further specific treatment needed), or with persistent 
occlusion and mismatch (will receive EVT with time delay as compared with option 2). 
The time to admission to the EVT- SC will be determined by the initial distance to the 
Local-SC, the door-in/door-out (DIDO) time and the distance from Local SC to EVT- 
SC.
Option 2: Transfer to the nearest EVT-SC (bypassing the nearest local-SC) offers access 
to all effective treatments. The time to admission will only be determined by the 
distance to the EVT-SC. As compared to option 1, iv thrombolysis treatment is delayed 
(or even denied) but EVT initiation is advanced.
Patient population
The RACECAT study is being performed in the autonomous region of Catalonia, with 
the participation of Emergency Medical Services (EMS) and all the Stroke Centers: 6 
Endovascular Stroke Centers (EVT-SC) and 19 Local Stroke Centers (Local-SC), 7 of 
them Primary Stroke Centers and 12 Telestroke Centers.9 
The healthcare system of Catalonia integrates into a single network of public use 
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(SISCAT) all health resources to cover the entire population (7.5 million residents). As 
for acute stroke care, territorial planning occurred between 2006 and 2013 that 
eventually rolled out a network of Code Stroke hospitals dotted around Catalonia. The 
EMS, a public company within the SISCAT, is responsible for urgent prehospital care 
including Code Stroke patients as well as urgent interhospital transports. The Code 
Stroke Instruction of Catalonia set the activation criteria to be satisfied by the EMS 
upon acute stroke recognition, and all the Code Stroke-related EMS activity is included 
in the SITREM registry. In addition, the Code Stroke Instruction also established the 
need to continuously monitor the quality of the model based on mandatory inclusion of 
Code Stroke patients’ data in a prospective registry (CICAT). 
RACECAT eligible population includes patients located in geographical areas where 
the reference stroke center is a hospital not capable to offer EVT, covering a total 
population of 3.85 million inhabitants, with distance to an EVT-SC ranging from 20 
to150 minutes, and an average transfer time between centers of 45 minutes.
Patient eligibility criteria
Inclusion criteria: 
1. Stroke patients with suspected LVO identified by a RACE scale9 score >4 evaluated 
by EMS professionals previous to the transfer to a stroke center: at the pre-hospital 
setting, in non-stroke ready centers or primary healthcare centers.
2. Patients located in geographical areas where the reference stroke center is a hospital 
not capable to offer EVT (Primary stroke Center or Telestroke Center).
3. Estimated arrival time to an EVT-SC <7 hours from symptom onset. Symptom onset 
is defined as the time in which the patient was last seen well.
4. No significant pre-stroke functional disability (modified Rankin scale 0 - 2)
5. Age ≥18
6. Deferred informed consent obtained from patient or acceptable patient surrogate 
(after the acute phase, as permission to use clinical data within a clinical registry was 
approved by the ethics committee)
Exclusion criteria
1. Patients in a coma (NIHSS item of consciousness >1).
2. Patients with unstable clinical status who require emergent life support care.
3. Serious, advanced, or terminal illness with anticipated life expectancy of less than 6 
month.
4. Acute stroke patients with suspected LVO identified at the Emergency Department of 
a stroke center. 
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5. Subjects participating in a study involving an investigational drug or device if it is 
believed that participation in such a study  would impact the results of this  study.
6. Patients with a pre-existing neurological or psychiatric disease that would impair the 
neurological or functional evaluation. 
7. Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor 
from overseas).
Randomization
EMS pre-alert to the stroke neurologist before randomization
To ensure a high sensitivity to identify candidate patients, EMS contact the stroke 
neurologist on call by telephone upon identification of an acute stroke patient with the 
following conditions: RACE scale score >3 and time from symptom onset or last time 
seen well <8 hours. After EMS contact, the stroke neurologist confirms all the inclusion 
criteria and enrolls the patient in the RACECAT study.
Randomization
Consistent with the temporal cluster design of our study, transfer allocation to each of 
the two arms was carried out in a 1:1 ratio by 12-hour time-slots, following a 
randomized temporal schedule previously defined by an external statistician (Bioclever) 
and stratified by territory (metropolitan vs. provincial area) and week day (working vs. 
weekend day). This stratification was decided with the aim to ensure a balanced 
distribution between the two groups regarding the urban vs. rural location of the patient, 
the proportion of wake-up strokes, and the proportion of patients attended in non-
working hours, which are factors that can influe ce access to EVT and clinical 
outcomes.  The choice of randomization by 12-hour blocks of time, rather than by days 
or weeks, was set in order to ensure the least amount of blinding regarding transfer 
allocation. 
Allocation
Assignment of the patient to one out of the two possible transfer options is performed in 
real time by a smartphone based automated system according to the predefined 
randomized time period schedule. During the EMS contact, the stroke neurologist enters 
basic data of the patient into the system and immediately receives the assigned 
intervention group and the study code number, that is communicated to the EMS 
coordination center so that the transfer can be consequently organized by the EMS. 
A notification is automatically sent from the allocation software to the local investigator 
of the receiving center and to the data managers for every included patient. Moreover, 
the EMS coordinator center and the Stroke neurologist alert the physician in charge at 
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the allocated destination center (Local-SC or EVT-SC) of the upcoming urgent arrival 
of a newly included patient in the study. 
Masking
Transfer group allocation cannot be blinded to EMS professionals or neurologists that 
attend the patient at the Stroke Center (Local-SC or EVT-SC). Although this might 
open the way to performance bias, all involved professionals are encouraged to treat the 
patients according to best clinical practice. Local investigators of the participating 
Stroke Centers, who are not blinded to the assigned group, will register secondary 
outcomes (risk of evaluation bias). However, in all patients, the primary outcome 
(modified Rankin Scale score at 90 days), is evaluated through a telephone call by a 
certified central assessor, blinded to group assignment. 
Intervention
Patients included in the study are assigned to two different transfer models (Figure 1): 
- Local-SC: Transfer to closest Local-SC as currently stated on the standard code stroke 
protocol (reference intervention).
- EVT-SC: Directly transferred to the EVT-SC bypassing the closest Local-SC 
(experimental intervention)
For patients allocated to the EVT-SC group with estimated transfers longer than 60 
minutes, the following transport resources are prioritized as follow:
1. Helicopter Emergency Medical Services (with physician): 
2. Advanced Life Support (with physician or nurse) 
3. Basic Life Support (with emergency technicians) if an advanced ambulance is not 
immediately available. 
Modification of allocated intervention
Modification or change of the allocated circuit is only allowed when neurological 
deterioration or severe medical complications during the transfer occur. In such case, 
the patient is transported to the nearest stroke center as soon as possible. All other 
deviations from initial destination due to other reasons will be analyzed as intention to 
treat but not in per protocol (see the Statistical Plan in the suplemental data).
Concomitant care and interventions prohibited during the trial
Other than initial decision about first transfer option patients receive standard clinical 
care according to each institutional protocols of each participating center, always in 
agreement with European Stroke Organization and national guidelines. 
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In local-SC, evaluation of EVT criteria and transfer to accredited EVT-SC when needed 
is mandatory for all patients. Contact with the EVT team from the local-SC is 
performed immediately after the neuroimaging confirming a LVO ischemic stroke or 
based on plain CT plus clinical criteria (NIHSS>=6 with cortical signs) in centers where 
vascular neuroimaging is not available, without waiting for response to iv-tPA if 
administered. Patients included in the RACECAT trial will not receive EVT at any 
center not recognized as an EVT-SC by the local authorities.
Outcomes
Primary outcome
The primary outcome is the modified Rankin Scale score at 90 days in ischemic stroke 
patients as evaluated through a structured telephone-based interview performed by a 
central assessor who is blinded to group assignment.
The primary analysis is the shift analysis of the mRS (with values 5, severe disability, 




1. To explore whether time to endovascular stroke center arrival, plays any role on the 
consistency of the intervention effect 
2. To explore the consistency of the main effect on the (shift analysis) in the following 
populations: All patients / hemorrhagic / mimics 
3. To explore the consistency of the main effect on the following subgroups:
a. Age <80  //  ≥ 80
b. Gender male // female
c. Eligible for iv t-PA // non iv t-PA eligible when attended by EMS 
d. Treatment with iv tPA // no treatment with iv tPA at the first hospital 
admission
e. Confirmed prior mRS 0-2 // mRS >2 evaluated at hospital arrival
f. Patients with values RACE scale 5-7 // RACE 8-9
4. Proportion of patients receiving iv tPA 
5. Proportion of patients receiving EVT
6. Time from symptom onset to iv tPA administration (for patients treated with iv tPA) 
and to groin puncture (for patients treated with endovascular)
7. Dramatic early favorable response as determined by an NIHSS of 0-2 or NIHSS 
improvement ≥ 8 points at 24 (-2/+12 hours) hours in patients with ischemic stroke.
Secondary Safety outcomes
1. Mortality at 90 days in all patients.
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2. Mortality at 90 days in intracerebral hemorrhage (ICH) patients.
3. Clinical deterioration requiring intubation during primary or secondary transfers.
4. Clinical deterioration (≥4 points on the NIHSS) at 24 hours.
Fig 2 shows the schedule of enrolment, interventions and assessments.
Data monitoring
Data collection
Trial data are part of the routinely collected data in ongoing stroke registries already 
implemented in Catalonia at the time of trial kickoff. For any given RACECAT patient, 
the data flow includes the following cohorts: SITREM, for prehospital EMS-related 
data; TICAT, for prehospital telestroke neurologist assessment of Code Stroke patients; 
and CICAT, for hospital-based data of Code Stroke patients (Figure 3).  
The RACECAT electronic case report form is embedded in the CICAT registry since 
this dataset is linked to the SITREM and TICAT registries and captures specific 
information for the prehospital process of care. CICAT is a government-mandated, 
population-based registry of all Code Stroke activations reaching and being evaluated at 
any Stroke Center in Catalonia, where local investigators are responsible for registering 
any new case during admission. The CICAT registry has been adapted to include all 
data required for the RACECAT study (i.e. complications occurring during urgent EMS 
transfers, and the 5-day/ discharge visit). Since within our Code Stroke network, a given 
patient may be attended at different centers during the process of care, different 
investigators from different centers can fill in the different levels of the CICAT registry 
(Fig 1, supplementary data). 
Every working day, a full-time dedicated general study coordinator (neurologist) checks 
all the patients included in the RACECAT study, confirms the signature of the informed 
consent by the patient or relatives, and contacts the participating centers to assure the 
compliance with the protocol and inclusion of clinical data in the registries. 
Informed consent
Either patients or their legal representatives sign the informed consent form upon 
hospital arrival. Since inclusion of all Code Stroke cases in the CICAT registry is 
mandatory, the informed consent asks for permission to use all registry data within the 
framework of the trial, and for the telephone-based follow-up at 90 days. For cases in 
whom written consent cannot be obtained during hospital admission is not possible, the 
central coordinator makes efforts to obtain an oral, recorded consent through telephone 
call. For those other cases in whom written or oral consent cannot be obtained at any 
time, only a selection of unmonitored data included in the mandatory CICAT registry is 
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used for the study purposes. Patients without informed consent are not contacted at 90 
days over the phone and the last mRS value (visit 5d) is carried forward. If informed 
consent is denied the patient’s information will not be used in efficacy analyses, but 
vital status at 90 days will be included for safety analysis.
Data Auditing
All data entered in the CICAT registry are monitored by an external CRO (Anagram) 
through centralized monitoring performed at some of the participating centers where 
electronic health records for all Catalan citizens can be centrally accessed. Any data 
discrepancies are queried to the local investigator. Monitoring visits are performed to 
verify data accuracy and ensure queries are resolved.
Screening-log
RACECAT is designed as a population-based study. Monitoring of adherence to the 
study selection criteria is performed through monthly reviews of the EMS database 
(SITREM) to detect code stroke patients with RACE scale >4 not included in the study. 
Patients not included because EMS did not contact the stroke neurologist are registered 
as “potentially eligible but unscreened”. Patients not included because the stroke 
neurologist detected any exclusion criteria are considered as “screening failures” and 
are registered in the TICAT database (Figure 3). Feed-back about the adherence to the 
study protocol is given to all investigators every month. Additional meetings take place 
in case of detecting inclusion problems in specific geographic areas.
Data Safety Monitoring Board (DSMB)
An independent Data Safety Monitoring Board has been established. The purpose of the 
DSMB is to review, on a regular basis, accumulating data from the ongoing trial. The 
DSMB also evaluates the interim analyses, which are performed by an external 
statistician (Bioclever), according to the pre-written statistical analysis plan (Charter 
DSMB, Supplemental data). The DSMB is composed of three experienced stroke 
neurologists who are not participating in the study and are not affiliated with the 
sponsor. The DSMB could require the assistance of a statistician if considered 
necessary. The role of the DSMB is to: (1) make recommendations to the Study 
Executive Committee regarding stopping or extending the trial based on the pre-planned 
interim analysis; and (2) review the occurrence of adverse events and make 
recommendations to the Executive Committee regarding safety of the study. A strict 
control of predefined adverse events is ensured through monitoring by the CRO. The 
following SAEs are specially monitored: (1) Aspiration pneumonia within 5 days; (2) 
Clinical deterioration requiring intubation during EMS transfer to the stroke center 
assigned; (3) Clinical deterioration during the first 24h.




Effect size measure 
According to data available from the RACE score validation study, we can assume that 
final diagnostic of patients with a RACE >4 for both groups of study are: 5% stroke 
mimics, 20% intracerebral hemorrhage (ICH), 25% acute ischemic stroke without LVO 
or re-canalized with iv-tPA (AIS-no LVO), 50% acute ischemic stroke with a persistent 
LVO (AIS-LVO). As ischemic patients constitute the target population, sample size 
calculation is based on the enrichment studies paradigm. As the expected ischemic and 
non-ischemic ratio is 3:1, recruited sample will be increased accordingly.
The proportion of ischemic stroke patients treated with EVT is estimated to be 30-35% 
in the EVT-SC group and 12% in the Local-SC based on the ex-ante rates in the areas 
directly covered by an EVT-SC and areas applying a drip-and-ship model. For the 
estimation of good outcome in each group, we considered the proportion of patients 
with good outcome (mRS≤2) for each particular diagnostic and treatment accordingly 
with previous scientific evidence: AIS-LVO treated with EVT (55%), AIS-LVO treated 
with EVT transferred from Local-SC (45%, expecting that onset to treatment in the 
Local-SC group will be probably 60 minutes longer, that corresponds to a 10% lower 
rate of good outcome according to a sub-analysis of REVASCAT trial), AIS-LVO not 
receiving EVT (30%) and AIS-no LVO (50%). Taking into account the expected 
distribution of diagnostics and treatments, the rate of good outcomes (mRS≤2) at 90 
days for the intervention arm (direct to an EVT-SC) is estimated to be around 44%, and 
for the control arm (transferred to a Local-SC) is estimated to be 38% (Fig 4). These 
estimates yield an expected difference of 6% in the proportion of good outcome (mRS 
≤2) (Figure 4).
Interim analyses rationale
We desired a maximum of 3 looks when approximately 40, 70 and 100% of the sample 
size complete the 90 days of follow-up, plus monitoring and data cleaning processes. A 
sequential test strategy was designed to have reasonable chances of stopping as soon as 
possible, either because of better efficacy of the intervention, because of the futility of 
the trial or because of safety reasons (Table 1). 
At interim analysis, in case the stopping boundaries are crossed, the DSMB will 
recommend stopping the study either for efficacy, futility or safety (supplemental data). 
When addressing safety, DSMB will also consider mortality (mRS=6) and severe 
dependency (mRS=5) at three months as one single value. Once the interim analysis has 
been completed, the final decision to stop the study will be made by the steering 
committee at the recommendation of the data safety monitoring board. In case of early 
stopping, any overrunning patient will be followed until the end of the study and a final 
analysis will be performed.
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Devised effect, power and sample size
The RACECAT trial is designed to test a shift common OR=1.348. We also analyze the 
trial properties under alternate more optimist (8%, 10%) and pessimistic (0%, 4%) 
scenarios. The ischemic population sample size required with these expected 
proportions and assuming one-sided Type I and Type II error probabilities of 0.025 and 
0.20, respectively, is 1316. A triangular test with 2 interim looks (40/70% of sample 
recruitment) plus 1 final analysis is specified11. The number of patients and the 
theoretical probabilities to stop for efficacy or for futility at each interim look is showed 
in Table 1. Total sample size, including non-ischemic patients that will not compute for 
the final efficacy analysis is 1754. 
An overall of 1316 ischemic patients (658 patients in each group) will provide a one-
sided alpha risk of 2.5% if both compared treatments perform equally. The power will 
be 47.5% (80%, 95.5% and 99.4%) if the intervention improves by 4% (6%, 8% and 
10%). Chances of stopping at each interim arm are also provided in table 1. For the 6% 
improvement, the theoretical probabilities of stopping at interim 1 (2 and 3) with a 
positive result of higher intervention efficacy are 32.8% (33.3% and 13.9%). 
Statistical design
Primary end-point analysis 
Main analysis is a common OR over th  first 5 cut-points along the modified Rankin 
Scale (mRS) (shift analysis) at 90 days analyzed by Ordinal Logistic Regression. 
Therefore, the two worst mRS values (5 and 6) are treated as equal in the analyses.
Analysis of safety end-points
Mortality at 90 days will be assessed for all enrolled subjects and specifically for ICH 
patients. A Kaplan–Meier analysis will be generated and the mortality rates at 90 days 
between arms will be compared and 95% confidence intervals will be reported. Every 
attempt will be made to determine the status of each subject who withdraws from the 
study so that the withdrawal data can be used as a censoring point. A descriptive 
analysis of study-defined adverse events will be presented in aggregate and by event. 
Moreover, a descriptive analysis of other study-defined safety end-points will be 
presented, as clinical deterioration requiring tracheal intubation and clinical 
deterioration at 24h (NIHSS worsening ≥4 points or death at 24h).
A safety and administrative analysis will be performed after inclusion of the first 100 
patients and thereafter every additional 300 enrolled patients. These analyses will be 
evaluated by the DSMB.
Ethics and dissemination
The RACECAT study protocol was approved by the local ethics committee of all 




Any modifications to the protocol which may impact on the conduct of the study, 
potential benefit of the patient or may affect patient safety, including changes of study 
objectives, study design, patient population, sample sizes, study procedures, or 
significant administrative aspects will require a formal amendment to the protocol. Such 
amendments will be approved by the corresponding Ethics Committees prior to 
implementation and notified to the health authorities in accordance with local 
regulations.
Conclusion
The RACECAT study aims to provide evidence that will help determine best practice in 
the prehospital workflow and management of suspected large vessel occlusion acute 
stroke patients.
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Table 1. Theoretical properties of the Triangular design for total N=1754 (N for 
ischemic=1316). Percentages indicates the probability of stopping at any interim, either 
for futility, for efficacy (‘positive’) or for any reason (‘both’), considering the different 
values of the treatment effect : the difference in the success rate. To facilitate reading, 
numbers are rounded and some percentages may not add up to 100%.
OLR (hypothetical)
  H0: OR=1 (Δ=0) H1: OR=1.225 (Δ=4%) H1: OR=1.348 (Δ=6%)
H1: OR =1.478 
(Δ=8%)





ischemic Futility Positive Both Futility Positive Both Futility Positive Both Futility Positive Both Futility Positive Both






% 0,3% 76,8% 77,0%






% 0,3% 20,7% 21,0%




% 1,2% 7,1% 8,3% 0,1% 1,9% 2,0%
  97,5% 2,5% 100% 52,5% 47,5% 100% 20,0% 80,0% 100% 4,5% 95,5% 100% 0,6% 99,4% 100%
Prob(Total 






% 0,4% 22,6% 23,0%
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Figure 1. Intervention. Patients included in the study are assigned to two different 
transfer models: circuit A (drip and ship) and circuit B (mother ship).
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Stroke Neurologist confirmation X
Eligibility criteria X
Allocation (randomization 
program by internet used by the 
Telestroke neurologist)
X
Registry on the TICAT registry 
(Telestroke neurologist) X





Direct transfer to Ev-SC X
Transfer to the Local-SC X
Secondary transfer from Local-
SC to CSC (if candidate to EVT) XX
Return to the Local-SC XX(if necessary)
Assessments:
Iv-tPA eligible when attended by 
EMS X
Clinical deterioration during 
transfer X X






(iv-tPA or/and EVT) X
Time to reperfusion therapy X
NIHSS at 24h (-2/+12h) X
Severe adverse events X X X
mRS at 90 days1 X
Cost of care (parallel study) X
1mRS to be done by an independent blinded evaluator through a structured telephone based interview.
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Figure 3. Data collection
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Figure 4. Estimated effect of the intervention, based on the diagnostic distribution and 
on the access to EVT in both groups.
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